Development of intestinal, but not gastric damage caused by a low dose of indomethacin in the presence of rofecoxib

Inflammopharmacology

Volumn 13, Issue 1-3, 2005, Pages 209-216

  Yokota, Aya ^a   Taniguchi, Masaki ^a   Tanaka, Akiko ^a   Takeuchi, Koji ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

COX 2 expression; Indomethacin; Intestinal damage; Motility; Rat; Rofecoxib gastric damage; Selective COX 2 inhibitor

Indexed keywords

INDOMETACIN; ROFECOXIB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; GASTROINTESTINAL TRACT; INTESTINE; LOW DRUG DOSE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STOMACH INJURY; STOMACH MOTILITY;

AMPICILLIN; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ATROPINE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DINOPROSTONE; DOSE-RESPONSE RELATIONSHIP, DRUG; GASTRIC MUCOSA; GASTROINTESTINAL MOTILITY; GENE EXPRESSION; GUANIDINES; INDOMETHACIN; INTESTINAL MUCOSA; INTESTINE, SMALL; LACTONES; MALE; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STOMACH; SULFONES;

EID: 27744575647     PISSN: 09254692     EISSN: None     Source Type: Journal    
DOI: 10.1163/156856005774423755     Document Type: Article

References (13)

1. Futaki, N., Takahashi, S., Yokoyama, M., et al. (1994). NS-398, a new antiinflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclo-oxygenase (COX-2) activity in vitro, Prostaglandins 47, 55-59.
2. Tso, J. Y., Sun, X. H., Kao, T. H., et al. (1985). Isolation and characterization of rat and human glyceraldehyde-3-phosphate dehydrogenase cDNAs: Genomic complexity and molecular evolutiojn of the gene, Nucleic Acids Res. 13, 2485-2502.
3. Konaka, A., Kato, S., Tanaka, A., et al. (1999). Roles of enterobacteria, nitric oxide and neutrophil in pathogenesis of indomethacin-induced small intestinal lesions in rats, Pharmacol. Res. 40, 517-524.
4. Reuter, B. K., Davies, N. M. and Wallace, J. L. (1997). Nonsteroidal anti-inflammatory drug enteropathy in rats: Role of permeability, bacteria, and enterohepatic circulation, Gastroenterology 112, 109-117.
5. Takeuchi, K., Ueki, S. and Okabe, S. (1986). Importance of gastric motility in the pathogenesis of indomethacin-induced gastric lesions in rats, Dig. Dis. Sci. 31, 1114-1122.
6. Takeuchi, K., Tanaka, A., Ohno, R., et al. (2002a). COX inhibition and NSAID-induced gastric damage, Pharmacol. Res. Trends 6, 69-81.
7. Takeuchi, K., Miyazawa, T., Tanaka, A., et al. (2002b). Pathogenic importance of intestinal hypermotility in NSAID-induced small intestinal damage in rats, Digestion 66, 30-41.
8. Tanaka, A., Araki, H., Hase, S., et al. (2001). Inhibition of both COX-1 and COX-2 is required for development of gastric damage in response to nonsteroidal antiinflammatory drugs, J. Physiol. 95, 21-27.
9. Tanaka, A., Hase, S, Miyazawa, T., et al. (2002a). Up-regulation of COX-2 by inhibition of COX-1: A key to NSAID-induced intestinal damage, J. Pharmacol. Exp. Ther. 300, 754-761.
10. Tanaka, A., Matsumoto, M., Katagiri, A., et al. (2002b). NSAID-induced small intestinal damage: Role of COX inhibition, Inflammopharmacology 10, 313-325.
11. Tanaka, A., Araki, H., Hase, S., et al. (2002c). Roles of COX-1 and COX-2 inhibition in nonsteroidal antiinflammatory drug-induced gastric damage in rats: Relation to functional responses, Aliment. Pharmacol. Ther. 16, 90-101.
12. Wallace, J. L., McKnight, W., Reuter, B. K., et al. (2000). NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2, Gastroenterology 119, 706-714.
13. Whittle, B. J. R. (1981). Temporal relationship between cyclooxygenase inhibition, as measured by prostacyclin biosynthesis and the gastrointestinal damage induced by indomethacin in rat, Gastroenterology 80, 94-98.